Inhibition of VEGF receptors induces pituitary apoplexy: an experimental study in mice

1.

Zirlik K, Duyster J. Anti-Angiogenics: Current Situation and Future Perspectives.

Oncol Res Treat. 2018; 41(4): 166-171. https://doi.org/10.1159/000488087.

PMID: 29562226.

2.

Babu R, Komisarow JM, Agarwal VJ, Rahimpour S, Iyer A, Britt D, et al.

Glioblastoma in the elderly: the effect of aggressive and modern therapies on

survival.

Neurosurg.

2016;

124(4):

998-1007.

https://doi.org/10.3171/2015.4.Jns142200. PMID: 26452121.

3.

Wang H, Guo J, Wang T, Wang K, Wu Z, Sun T. Efficacy and safety of

bevacizumab in the treatment of adult gliomas: a systematic review and metaanalysis. BMJ Open. 2021; 11(12): e048975. https://doi.org/10.1136/bmjopen2021-048975. PMID: 34857558.

4.

Zhu X, Tian X, Yu C, Hong J, Fang J, Chen H. Increased risk of hemorrhage in

metastatic colorectal cancer patients treated with bevacizumab: An updated metaanalysis of 12 randomized controlled trials. Medicine (Baltimore). 2016; 95(34):

e4232. https://doi.org/10.1097/MD.0000000000004232. PMID: 27559943.

5.

Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy

for

cancer.

Br

Cancer.

2007;

96(12):

1788-1795.

https://doi.org/10.1038/sj.bjc.6603813. PMID: 17519900.

6.

Elice F, Rodeghiero F. Side effects of anti-angiogenic drugs. Thromb Res. 2012;

129 Suppl 1: S50-53. https://doi.org/10.1016/S0049-3848(12)70016-6. PMID:

22682133.

7.

Kamba T, Tam BY, Hashizume H, Haskell A, Sennino B, Mancuso MR, et al.

VEGF-dependent plasticity of fenestrated capillaries in the normal adult

microvasculature. Am J Physiol Heart Circ Physiol. 2006; 290(2): H560-576.

https://doi.org/10.1152/ajpheart.00133.2005. PMID: 16172168.

8.

Dai C, Liang S, Sun B, Li Y, Kang J. Anti-VEGF Therapy in Refractory Pituitary

Adenomas and Pituitary Carcinomas: A Review. Front Oncol. 2021; 11: 773905.

https://doi.org/10.3389/fonc.2021.773905. PMID: 34869016.

9.

Shepard MJ, Snyder MH, Soldozy S, Ampie LL, Morales-Valero SF, Jane JA.

Radiological and clinical outcomes of pituitary apoplexy: comparison of

conservative management versus early surgical intervention. J Neurosurg. 2021:

1-9. https://doi.org/10.3171/2020.9.JNS202899. PMID: 33930863.

10.

Hojo M, Goto M, Miyamoto S. Chronic expanding pituitary hematoma without

rebleeding after pituitary apoplexy. Surg Neurol Int. 2013; 4: 41.

https://doi.org/10.4103/2152-7806.109654. PMID: 23607063.

11.

Kasl RA, Kistka HM, Turner JH, Devin JK, Chambless LB. Pituitary Apoplexy

After Intravitreal Injection of Vascular Endothelial Growth Factor Inhibitor: A

Novel

Complication.

Neurol

Surg

Rep.

2015;

76(2):

e205-210.

https://doi.org/10.1055/s-0035-1554909. PMID: 26623228.

12.

Garton AJ, Crew AP, Franklin M, Cooke AR, Wynne GM, Castaldo L, et al. OSI930: a novel selective inhibitor of Kit and kinase insert domain receptor tyrosine

kinases with antitumor activity in mouse xenograft models. Cancer Res. 2006;

66(2): 1015-1024. https://doi.org/10.1158/0008-5472.CAN-05-2873. PMID:

16424037.

13.

Macpherson IR, Poondru S, Simon GR, Gedrich R, Brock K, Hopkins CA, et al.

A phase 1 study of OSI-930 in combination with erlotinib in patients with

advanced

solid

tumours.

Eur

Cancer.

2013;

49(4):

782-789.

https://doi.org/10.1016/j.ejca.2012.09.036. PMID: 23099006.

14.

Yap TA, Arkenau HT, Camidge DR, George S, Serkova NJ, Gwyther SJ, et al.

First-in-human phase I trial of two schedules of OSI-930, a novel multikinase

inhibitor, incorporating translational proof-of-mechanism studies. Clin Cancer

Res. 2013; 19(4): 909-919. https://doi.org/10.1158/1078-0432.Ccr-12-2258.

PMID: 23403628.

15.

Percie du Sert N, Hurst V, Ahluwalia A, Alam S, Avey MT, Baker M, et al. The

ARRIVE guidelines 2.0: Updated guidelines for reporting animal research. PLoS

Biol. 2020; 18(7): e3000410. https://doi.org/10.1371/journal.pbio.3000410.

PMID: 32663219.

16.

Marumo T, Takagi Y, Muraki K, Hashimoto N, Miyamoto S, Tanigaki K. Notch

signaling regulates nucleocytoplasmic Olig2 translocation in reactive astrocytes

differentiation after ischemic stroke. Neurosci Res. 2013; 75(3): 204-209.

https://doi.org/10.1016/j.neures.2013.01.006. PMID: 23396245.

17.

Lacoste B, Comin CH, Ben-Zvi A, Kaeser PS, Xu X, Costa Lda F, et al. Sensoryrelated neural activity regulates the structure of vascular networks in the cerebral

cortex.

Neuron.

2014;

83(5):

1117-1130.

https://doi.org/10.1016/j.neuron.2014.07.034. PMID: 25155955.

18.

Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for

medical

statistics.

Bone

Marrow

Transplant.

2013;

48(3):

452-458.

https://doi.org/10.1038/bmt.2012.244. PMID: 23208313.

19.

Vidal S, Lloyd RV, Moya L, Scheithauer BW, Kovacs K. Expression and

distribution of vascular endothelial growth factor receptor Flk-1 in the rat pituitary.

Histochem

Cytochem.

2002;

50(4):

533-540.

https://doi.org/10.1177/002215540205000410. PMID: 11897806.

20.

Onofri C, Theodoropoulou M, Losa M, Uhl E, Lange M, Arzt E, et al.

Localization of vascular endothelial growth factor (VEGF) receptors in normal

and adenomatous pituitaries: detection of a non-endothelial function of VEGF in

pituitary

tumours.

Endocrinol.

2006;

191(1):

249-261.

https://doi.org/10.1677/joe.1.06992. PMID: 17065408.

21.

Furube E, Mannari T, Morita S, Nishikawa K, Yoshida A, Itoh M, et al. VEGFdependent and PDGF-dependent dynamic neurovascular reconstruction in the

neurohypophysis of adult mice. J Endocrinol. 2014; 222(1): 161-179.

https://doi.org/10.1530/JOE-14-0075. PMID: 24860149.

22.

Horiguchi K, Yako H, Yoshida S, Fujiwara K, Tsukada T, Kanno N, et al.

S100beta-Positive Cells of Mesenchymal Origin Reside in the Anterior Lobe of

the Embryonic Pituitary Gland. PLoS One. 2016; 11(10): e0163981.

https://doi.org/10.1371/journal.pone.0163981. PMID: 27695124.

23.

Lindahl P, Johansson BR, Leveen P, Betsholtz C. Pericyte loss and

microaneurysm formation in PDGF-B-deficient mice. Science. 1997; 277(5323):

242-245. https://doi.org/10.1126/science.277.5323.242. PMID: 9211853.

24.

Soriano P. Abnormal kidney development and hematological disorders in PDGF

beta-receptor

mutant

mice.

Genes

Dev.

1994;

8(16):

1888-1896.

https://doi.org/10.1101/gad.8.16.1888. PMID: 7958864.

25.

Dejana E, Orsenigo F, Lampugnani MG. The role of adherens junctions and VEcadherin in the control of vascular permeability. J Cell Sci. 2008; 121(Pt 13):

2115-2122. https://doi.org/10.1242/jcs.017897. PMID: 18565824.

26.

Li W, Chen Z, Chin I, Chen Z, Dai H. The Role of VE-cadherin in Blood-brain

Barrier Integrity Under Central Nervous System Pathological Conditions. Curr

Neuropharmacol.

2018;

16(9):

1375-1384.

https://doi.org/10.2174/1570159X16666180222164809. PMID: 29473514.

27.

Satoh H, Inokuchi T, Shimizu M, Obayashi H, Nakashima Y. Ultrastructure of

the hypophyseal portal vessel in mature rats--SEM and TEM observations.

Kurume Med J. 1989; 36(3): 91-94. https://doi.org/10.2739/kurumemedj.36.91.

PMID: 2635249.

28.

Levidiotis M, Perry RA, Wintour EM, Oldfield BJ. Analysis of the appearance of

fenestrations in the blood vessels of the fetal sheep pituitary. Neuroendocrinology.

1991; 53(3): 222-228. https://doi.org/10.1159/000125722. PMID: 2041584.

29.

Inai T, Mancuso M, Hashizume H, Baffert F, Haskell A, Baluk P, et al. Inhibition

of Vascular Endothelial Growth Factor (VEGF) Signaling in Cancer Causes Loss

of Endothelial Fenestrations, Regression of Tumor Vessels, and Appearance of

Basement Membrane Ghosts. The American Journal of Pathology. 2004; 165(1):

35-52. https://doi.org/10.1016/s0002-9440(10)63273-7.

...